Julia Dudley

Julia Dudley

Auto-generated profile, based on publicly available information

Julia Dudley

Academic Department of Paediatrics, Royal Alexandra Children’s Hospital, Brighton, West Sussex, UK

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2016 in International Journal of Pediatric Otorhinolaryngology
Verified
Journal Article
Closed access
LTLorraine A. de Trey
Lorraine A. de Trey
JDJulia Dudley
Julia Dudley
HIHasnaa Ismail-Koch
Hasnaa Ismail-Koch
ADAndrew Durward
Andrew Durward
HBHannah Bellsham-Revell
Hannah Bellsham-Revell
GMGavin A. Morrison
Gavin A. Morrison

1 September 2025 in Archives of Disease in Childhood
Verified
Journal Article
Closed access
JDJulia R R Dudley
Julia R R Dudley
ASAnnalie Shears
Annalie Shears
GYGeorgina Yan
Georgina Yan
PHPaul T Heath
Paul T Heath
SLShamez N Ladhani
Shamez N Ladhani
KFKaty Fidler
Katy Fidler
Objective: Estimate the incidence of herpes simplex virus (HSV) infections in infants under 90 days in the UK and Ireland and describe clinical presentation and outcomes. Design: Prospective population-based national surveillance study of infants <90 days with HSV infection, using British Paediatric Surveillance Unit (BPSU) methodology (August 2019–February 2022). Results: 117 infants with confirmed HSV infection were identified (6.0 cases/100 000 live births (95% CI 4.9, 7.2)). One-third (34.5%) of infants were premature (24 hours after symptom onset. Infants with disseminated infections presented with non-specific signs of sepsis: 65.8% were afebrile and 73.7% had no SEM lesions. Median C reactive protein at presentation was 4 mg/L (IQR 1–14). Overall mortality was 23.9%, rising to 65.8% among infants with disseminated disease. Of the 41 infants with follow-up data at 24 months, 29.3% had neurodevelopmental impairment (11.8% SEM, 45% CNS, 25% disseminated). Conclusions: Infants with neonatal HSV can present without fever, SEM lesions or elevated infection markers; treatment delay is subsequently common. Outcomes remain poor with high case-fatality rates and long-term morbidity. Clinicians should have a low threshold for empirically testing for and treating herpes in unwell neonates.

30 September 2021
Verified
Conference Paper
Open access
PDF file
KFKaty Fidler
Katy Fidler
PHPaul Heath
Paul Heath
JDJulia Dudley
Julia Dudley
GYGeorgina Yan
Georgina Yan
RLRichard Lynn
Richard Lynn
Background Neonatal herpes simplex virus infection is a rare but dangerous condition with a high mortality and morbidity unless recognised and treated early. A recent study1 suggests that the UK incidence may have increased since the last national surveillance studies were undertaken 15 and 30 years ago.2,3 There is currently no national guidance on when to initiate treatment for suspected neonatal HSV. Rising numbers of HSV cases may support the wider use of empirical treatment. Objectives To define the: (1) current burden of HSV disease and virus types, in UK and Irish infants less than 90 days, over a two-year period, (2) types of HSV disease ie disseminated, meningoencephalitis or skin/eye/mouth disease, (3) presentations and management, (4) source of transmission, (5) antenatal risk factors. Methods Prospective surveillance of HSV infection in infants < 90 days of age in UK and Ireland commenced in July 2019 through the British Paediatric Surveillance Unit (BPSU). Paediatricians reporting cases were requested to complete a detailed semi-anonymised questionnaire. Case notifications & data from completed questionnaires during the first 18 months, July 2019 - Jan 2021, are reported here. Results 137 cases reported to BPSU: 8 were errors, 80 clinicians completed questionnaires, 21 confirmed duplicates, leaving 59 cases for analysis. Estimated incidence is 6.9 cases per 100 000 live births based on 2019 UK & Ireland birth rates. 31 (53%) male, 17 (29%) born <37 weeks. 21 (36%) had disseminated (blood pcr positive), 18 (30%) encephalitis and 20 (34%) skin/eye/mouth (SEM) disease. HSV1: 29 (49%), HSV 2: 25 (42%), unknown:5 (9%). More of those with disseminated and CNS disease had HSV2 infections and more with SEM disease had HSV1. Presenting features of disseminated disease were non specific and only 3/21 (14%) presented with a fever. 10/21 (47.6%) had a CRP of less than 20 at presentation, 11/21 (52.3%) had a transaminitis. Disseminated disease was present in 4/5 (80%) babies born at 37 weeks gestation. Aciclovir was commenced in 54/59 but in only 23/59 (39.0%) on the day of presentation. Overall mortality was 22% but 57% in those with disseminated disease. Mortality by gestation was 60% 37 weeks. Conclusions Incidence of neontatal HSV has doubled since the last national surveillance study. Mortality remains high and presenting features of disseminated disease are non-specific. Absence of fever in 86% of cases demonstrates that HSV should not only be considered in the assessment of the febrile infant. Awareness of this disease needs to be raised to enable early recognition and treatment. References Batra D, Davies P, Manktelow BN, et al. The incidence and presentation of neonatal herpes in a single UK tertiary centre, 2006–2013. Archives of Disease in Childhood 2014;99:916–921. Tookey P, et al. Surveillance of neonatal herpes in the British Isles 2004–2006. Submitted for publication. Tookey P1, Peckham CS. Neonatal herpes simplex virus infection in the British Isles. Paediatr Perinat Epidemiol 1996 Oct;10(4):432–42.

27 November 2023 in Archives of Disease in Childhood - Fetal and Neonatal Edition
Verified
Journal Article
Closed access
PDF file
GYGeorgina Yan
Georgina Yan
ASAnnalie Shears
Annalie Shears
JDJulia R Dudley
Julia R Dudley
PMPaddy McMaster
Paddy McMaster
KFKaty J Fidler
Katy J Fidler